Mersana Therapeutics, a Cambridge-based clinical stage biopharmaceutical firm, is making strides in developing antibody drug conjugates (ADC) to treat cancer patients with unmet needs. The company's flagship products include the B7-H4-targeted Dolasynthen ADC candidate, XMT-1660, and the immunosynthen ADC, XMT-2056. Mersana Therapeutics has entered research and development collaborations with Janssen Biotech and Merck KGaA, while also collaborating with Asana BioSciences for the development of ADC product candidates. Founded in 2001 as Nanopharma Corp., the company changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. is committed to improving the lives of cancer patients through cutting-edge research and development of ADCs.
Mersana Therapeutics's ticker is MRSN
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Mersana Therapeutics
It is mersana.com
Mersana Therapeutics is in the Healthcare sector
Mersana Therapeutics is in the Biotechnology industry
The following five companies are Mersana Therapeutics's industry peers: